Sucralose affects response to oral glucose load in obese

July 2, 2013
Sucralose affects response to oral glucose load in obese
For obese adults who do not use non-nutritive sweetener, sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in Diabetes Care.

(HealthDay)—For obese adults who do not use non-nutritive sweetener (NNS), sucralose affects the glycemic and insulin responses to an oral glucose load, according to a study published online April 30 in Diabetes Care.

M. Yanina Pepino, Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues examined the acute effects of sucralose ingestion on the metabolic response to an oral glucose load in 17 obese individuals who did not use NNS and were insulin sensitive. In a randomized crossover design study, participants underwent a five-hour modified on two occasions 10 minutes after consuming sucralose or water.

The researchers found that sucralose ingestion caused significantly greater incremental increases in peak concentrations and insulin area under the curve, as well as a greater peak rate, and caused significant decreases in insulin clearance and insulin sensitivity, compared with the control condition. For active glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, glucagon incremental area under the curve, or indices of sensitivity to the ?-cell response to glucose, there were no significant differences between the conditions.

"In conclusion, the results from our study demonstrate that sucralose affects the glycemic and hormonal responses to an oral glucose load in obese people who do not normally consume NNS," the authors write. "These findings support the notion that sucralose is not metabolically inert but has physiologic effects."

Tate & Lyle provided sucralose for the study.

Explore further: Insulin LY2605541 tops glargine for glycemic control in T1DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Bile acid sequestrant reduces glucose concentration in T2DM

January 30, 2013

(HealthDay)—For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, secretion, ...

Recommended for you

Engineered hot fat implants reduce weight gain in mice

August 20, 2015

Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose ...

Promising progress for new treatment of type 1 diabetes

July 30, 2015

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.